Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Highlights from ASCO 2019

Asst. Prof Bishal Gyawali and Monique Biryiana
Highlights from ASCO 2019 ( Asst. Prof Bishal Gyawali and Monique Biryiana )
3 Jun 2019

Clinical and translational results from the NEOSTAR study: Treating early-stage lung cancer with nivolumab plus ipilimumab

Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston, USA
Clinical and translational results from the NEOSTAR study: Treating early-stage lung cancer with nivolumab plus ipilimumab ( Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston, USA )
1 Jun 2019

Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
1 Jun 2019

KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal junction and gastric cancers

Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital, Barcelona, Spain
KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal junction and gastric cancers ( Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital, Barcelona, Spain )
1 Jun 2019

KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC

Dr Edward B. Garon - UCLA, Los Angeles, USA
KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC ( Dr Edward B. Garon - UCLA, Los Angeles, USA )
1 Jun 2019

Pembrolizumab is safe and effective and substantially increases overall survival in aNSCLC patients

Dr Edward B. Garon - UCLA, Los Angeles, USA
Pembrolizumab is safe and effective and substantially increases overall survival in aNSCLC patients ( Dr Edward B. Garon - UCLA, Los Angeles, USA )
1 Jun 2019

Comment: The success of immunotherapy means we have to change our mindset as we treat patients

Dr David Graham and Dr Edward B. Garon
Comment: The success of immunotherapy means we have to change our mindset as we treat patients ( Dr David Graham and Dr Edward B. Garon )
1 Jun 2019

Pembrolizumab comparable to chemotherapy for patients with advanced gastric or gastroesophageal junction cancers

Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital , Barcelona, Spain
Pembrolizumab comparable to chemotherapy for patients with advanced gastric or gastroesophageal junction cancers ( Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital , Barcelona, Spain )
1 Jun 2019

Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemotherapy

Dr Richard Schilsky and Dr Josep Tabernero
Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemotherapy ( Dr Richard Schilsky and Dr Josep Tabernero )
1 Jun 2019

Ovarian cancer: Current treatments and latest advances

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Ovarian cancer: Current treatments and latest advances ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
24 May 2019

Latest in ovarian cancer treatment

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Latest in ovarian cancer treatment ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
24 May 2019

Novel adoptive cell therapies for acute lymphoblastic leukaemia

Prof Rupert Handgretinger, Director and Chair, Children’s University Hospital and Department of Haematology/Oncology, Tübingen, Germany
Novel adoptive cell therapies for acute lymphoblastic leukaemia ( Prof Rupert Handgretinger, Director and Chair, Children’s University Hospital and Department of Haematology/Oncology, Tübingen, Germany )
24 May 2019